Small Molecules
27 January 2020
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases25 January 2020
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria25 January 2020
Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium24 January 2020
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma23 January 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development23 January 2020
Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)23 January 2020
BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders23 January 2020
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy22 January 2020
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients22 January 2020
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy22 January 2020
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD21 January 2020
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis21 January 2020
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis21 January 2020
Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis21 January 2020
HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic20 January 2020
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLCNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports